- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00708799
Efficacy of Macrolide Immunomodulation in Severe Sepsis.
Efficacy of Macrolide Immunomodulation in Severe Sepsis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- South Texas Health Care System, San Antonio, TX
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject, or legal representative, has given written informed consent.
- 18 years of age or older.
SIRS is defined as two or more of:
- Temperature > 38o C or < 36oC
- Heart rate > 90 beats/min
- Respiratory rate > 20 breaths/min or PaCO2< 32mmHg
- White blood cell count > 12.000/mm3; < 4000/mm3; or > 10% immature (band) forms.
- Presence of a suspected or proven infection. Patients with suspected infection must have evidence of an infection, such as white blood cells in a normally sterile body fluid, perforated viscus, chest x-ray consistent with pneumonia and associated with purulent sputum production, or a clinical syndrome associated with a high probability of infection (for example, purpura fulminans or ascending cholangitis).
Presence of one or more sepsis-associated organ failure. The onset of the first sepsis-associated organ failure must occur within the 48-hour period immediately preceding initiation of study drug infusion. A patient must have an organ failure attributable to the sepsis episode. The organ failure must be newly developed and not explained by underlying disease processes or by effects of concomitant therapy.
- Cardiovascular: An arterial systolic blood pressure (SBP) of 90 mm Hg or a mean arterial pressure (MAP) 70 mm Hg for at least 1 hour despite adequate fluid resuscitation, adequate intravascular volume status, or the need for vasopressors to maintain SBP 90 mm Hg or MAP 70 mm Hg.
- Renal: Average urine output <0.5 mL/kg/h for 1 hour despite adequate fluid resuscitation
- Respiratory: Evidence of acute pulmonary dysfunction PaO2/FiO2 300 and, clinical exam or pulmonary capillary wedge pressure not suggestive of volume overload. If pneumonia is the suspected site of infection, the patient must have a PaO2/FiO2 200.
- Hematology: Platelet count <80,000/mm3 or a 50% decrease in platelet count from the highest value recorded over the last 3 days.
- Unexplained metabolic acidosis: Defined by (1) pH 7.30 or base deficit 5.0 mEq/L or (2) plasma lactate level >1.5 times the upper limit of normal.
Adequate fluid resuscitation or adequate intravascular volume is defined as either pulmonary arterial wedge pressure 12 mm Hg or central venous pressure 8 mm Hg. Vasopressors is defined as dopamine 5 g/kg/min or any dose of norepinephrine, epinephrine, or phenylephrine. Dobutamine is not considered a vasopressor.
Exclusion Criteria:
- Macrolide therapy indicated for clinical condition. If after randomization, the treating physician determines that a macrolide is indicated and no other alternative antibiotic is appropriate, the patient will be excluded from the trial. However, if only one dose of azithromycin had been given and the treating physician decided to stop it, azithromycin might be administered.
- Known allergy to macrolides.
- Prolonged QT syndrome or on medications with increased risk of QT prolongation.
- Pregnant or lactating.
Immunosuppression as defined by:
- Chemotherapy within the last 30 days,
- Leukemia or lymphoma which is not in remission,
- Solid organ or bone marrow/stem cell transplant,
- Human Immunodeficiency Virus infection with CD4 count < 200 cells/mm3,
- Chronic corticosteroid use equivalent to > 10 mg prednisone per day,
- Patient or family decision to limit ICU care.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
Standard antibiotic therapy +Azithromycin 500 mg intravenously daily for 5 days
|
One dose of azithromycin prior to inclusion to the RCT
Other Names:
|
No Intervention: Arm 2
Standard antibiotic therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in cytokines expression
Time Frame: Between admission and day five of treatment
|
Between admission and day five of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
28-day mortality
Time Frame: 28 days or discharge
|
28 days or discharge
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Marcos I Restrepo, MD BA MSc, South Texas Health Care System, San Antonio, TX
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VISN 17-001
- 5K23HL096054-03 (U.S. NIH Grant/Contract)
- UHS#20151 (Other Identifier: UTHSCSA/South Texas Veterans Health Care System)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Inflammatory Response Syndrome
-
University of CologneCompletedSystemic Inflammatory Response Syndrome (SIRS)Germany
-
Arkansas Children's Hospital Research InstituteEunice Kennedy Shriver National Institute of Child Health and Human Development...TerminatedSIRS (Systemic Inflammatory Response Syndrome(United States
-
Medical University of GdanskCompletedInflammatory Response Syndrome, Systemic | Granulocyte Immature FormsPoland
-
Chinese PLA General HospitalCompletedSepsis | SIRS(Systemic Inflammatory Response Syndrome)China
-
Chinese PLA General HospitalUnknownSepsis | SIRS(Systemic Inflammatory Response Syndrome)China
-
ImmunexpressJohns Hopkins University; Northwell Health; Rush University Medical Center; Intermountain... and other collaboratorsCompletedSepsis | Systemic Inflammatory Response Syndrome (SIRS)United States
-
Seattle Children's HospitalImmunexpressCompletedSepsis | Systemic Inflammatory Response Syndrome (SIRS)United States
-
University of ArkansasTerminatedPediatric Patients With SIRS (Systemic Inflammatory Response Syndrome)United States
-
University Hospital, LimogesTerminatedSevere Sepsis | Inflammatory Response Syndrome, SystemicFrance
-
Seattle Children's HospitalImmunexpressCompletedSepsis | Non-Infectious Systemic Inflammatory Response SyndromeUnited States
Clinical Trials on Azithromycin on admission - not enrolled in the RCT
-
University of California, BerkeleyUnited States Agency for International Development (USAID); Impact Carbon,... and other collaboratorsCompletedBehavior | Air Pollution, IndoorUnited States, Uganda
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)Completed
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Medical University of ViennaCompletedSepsis | Healthy VolunteersAustria
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Indiana UniversityCompletedMetastatic Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedNeuroblastomaUnited States